Skip to content

Clinical trials

Phase 2 Thyroid Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Thyroid Neoplasms Phase: Phase 2 Clear all

150 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20012
20033
200412
20056
20066
20076
20086
20095
20106
20111
20124
20138
20146
20156
20166
201711
20184
20194
202014
20217
20226
20233
20245
20256
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed72
Active, not recruiting21
Recruiting18
Terminated17
Unknown status17
Withdrawn2
Not yet recruiting2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)22
Fudan University8
Memorial Sloan Kettering Cancer Center7
M.D. Anderson Cancer Center6
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)4
Dana-Farber Cancer Institute3
Eisai Inc.3
Genzyme, a Sanofi Company3
University of Michigan Rogel Cancer Center3
Amgen2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Thyroid Neoplasms150
Thyroid Cancer, Papillary33
Adenocarcinoma, Follicular28
Carcinoma, Medullary21
Thyroid Carcinoma, Anaplastic21
Head and Neck Neoplasms16
Sarcoma9
Melanoma8
Neoplasms8
Carcinoma, Non-Small-Cell Lung7

Trials

Showing 51 to 75 of 150. Each trial links to its page on Pharma Observatory.

50 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.